These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26900470)

  • 21. Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis.
    Chopra M; Riedel SS; Biehl M; Krieger S; von Krosigk V; Bäuerlein CA; Brede C; Jordan Garrote AL; Kraus S; Schäfer V; Ritz M; Mattenheimer K; Degla A; Mottok A; Einsele H; Wajant H; Beilhack A
    Carcinogenesis; 2013 Jun; 34(6):1296-303. PubMed ID: 23385062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
    Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
    Front Immunol; 2018; 9():583. PubMed ID: 29623079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells.
    Schneider A; Rieck M; Sanda S; Pihoker C; Greenbaum C; Buckner JH
    J Immunol; 2008 Nov; 181(10):7350-5. PubMed ID: 18981158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TNF receptor 2 signaling prevents DNA methylation at the
    Tseng WY; Huang YS; Clanchy F; McNamee K; Perocheau D; Ogbechi J; Luo SF; Feldmann M; McCann FE; Williams RO
    Proc Natl Acad Sci U S A; 2019 Oct; 116(43):21666-21672. PubMed ID: 31597740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
    Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
    Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responses.
    Chissumba RM; Luciano A; Namalango E; Bauer A; Bhatt N; Wahren B; Nilsson C; Geldmacher C; Scarlatti G; Jani I; Kestens L;
    Immunobiology; 2018 Dec; 223(12):792-801. PubMed ID: 30121146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
    Zou H; Li R; Hu H; Hu Y; Chen X
    Front Immunol; 2018; 9():594. PubMed ID: 29632537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells.
    He X; Landman S; Bauland SC; van den Dolder J; Koenen HJ; Joosten I
    PLoS One; 2016; 11(5):e0156311. PubMed ID: 27224512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered Suppressor Function of Regulatory T Cells in Type 1 Diabetes.
    Aghili B; Amirzargar AA; Rajab A; Rabbani A; Sotoudeh A; Assadiasl S; Larijani B; Massoud A
    Iran J Immunol; 2015 Dec; 12(4):240-51. PubMed ID: 26714416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity.
    Atretkhany KN; Mufazalov IA; Dunst J; Kuchmiy A; Gogoleva VS; Andruszewski D; Drutskaya MS; Faustman DL; Schwabenland M; Prinz M; Kruglov AA; Waisman A; Nedospasov SA
    Proc Natl Acad Sci U S A; 2018 Dec; 115(51):13051-13056. PubMed ID: 30498033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imbalance between subpopulations of regulatory T cells in COPD.
    Hou J; Sun Y; Hao Y; Zhuo J; Liu X; Bai P; Han J; Zheng X; Zeng H
    Thorax; 2013 Dec; 68(12):1131-9. PubMed ID: 23749814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3- Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy.
    Li Z; Vermeire S; Bullens D; Ferrante M; Van Steen K; Noman M; Rutgeerts P; Ceuppens JL; Van Assche G
    Inflamm Bowel Dis; 2015 Oct; 21(10):2418-28. PubMed ID: 26308438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD 127- and FoxP3+ expression on CD25+CD4+ T regulatory cells upon specific diabetogeneic stimulation in high-risk relatives of type 1 diabetes mellitus patients.
    Vrabelova Z; Hrotekova Z; Hladikova Z; Bohmova K; Stechova K; Michalek J
    Scand J Immunol; 2008 Apr; 67(4):404-10. PubMed ID: 18248531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine.
    Faustman DL; Davis M
    Front Immunol; 2013 Dec; 4():478. PubMed ID: 24391650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity.
    Ukena SN; Höpting M; Velaga S; Ivanyi P; Grosse J; Baron U; Ganser A; Franzke A
    Exp Hematol; 2011 Dec; 39(12):1152-60. PubMed ID: 21864487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
    Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
    J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic Inflammation Increases the Sensitivity of Mouse Treg for TNFR2 Costimulation.
    Schmid T; Falter L; Weber S; Müller N; Molitor K; Zeller D; Weber-Steffens D; Hehlgans T; Wajant H; Mostböck S; Männel DN
    Front Immunol; 2017; 8():1471. PubMed ID: 29163535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T regulatory lymphocytes in type 1 diabetes: Impaired CD25 expression and IL-2 induced STAT5 phosphorylation in pediatric patients.
    Parackova Z; Kayserova J; Danova K; Sismova K; Dudkova E; Sumnik Z; Kolouskova S; Lebl J; Stechova K; Sediva A
    Autoimmunity; 2016 Dec; 49(8):523-531. PubMed ID: 27560779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells.
    Brode S; Raine T; Zaccone P; Cooke A
    J Immunol; 2006 Nov; 177(10):6603-12. PubMed ID: 17082572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
    Bluestone JA; Buckner JH; Fitch M; Gitelman SE; Gupta S; Hellerstein MK; Herold KC; Lares A; Lee MR; Li K; Liu W; Long SA; Masiello LM; Nguyen V; Putnam AL; Rieck M; Sayre PH; Tang Q
    Sci Transl Med; 2015 Nov; 7(315):315ra189. PubMed ID: 26606968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.